GlaxoSmithKline Pakistan Limited (PSX:GLAXO)

Market Cap	125.52B
Revenue (ttm)	62.07B
Net Income (ttm)	9.19B
Shares Out	318.47M
EPS (ttm)	28.85
PE Ratio	13.66
Forward PE	11.38
Dividend	10.00 (2.54%)
Ex-Dividend Date	Sep 5, 2025

Volume	69,064
Average Volume	117,164
Open	397.00
Previous Close	393.01
Day's Range	391.00 - 398.00
52-Week Range	301.00 - 481.00
Beta	0.34
RSI	46.77
Earnings Date	Mar 4, 2026

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan. It deals in anti-infective, dermatology, respiratory, immunology, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Pakistan Limited is a subsidiary of GSK plc.

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 2001
• Employees: 1,700
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: GLAXO

Financial Performance

In 2024, GlaxoSmithKline Pakistan's revenue was 61.19 billion, an increase of 23.21% compared to the previous year's 49.66 billion. Earnings were 6.54 billion, an increase of 1124.09%.